Drug Type T-lymphocyte cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism T lymphocyte replacements |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization- |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome | Phase 1 | United States | - | 22 Mar 2022 |